Thetis Pharmaceuticals, a developer of immuno-resolving therapies for treatment of inflammatory bowel disease, has received a Fast-Track Small Business Innovation Research Grant from the National Institutes of Health. The award provides up to $2.3 million to support development of Thetis’ TP-317 candidate as oral therapy for treatment of ulcerative colitis.
“TP-317 offers a fundamentally new approach to IBD treatment based on active resolution of inflammation and the promotion of tissue regeneration without suppressing the immune system. The grant will support the advancement of this promising, potential new therapy into the clinic.” said Gary Mathias, co-founder and chief executive officer at Thetis.